Justia Contracts Opinion Summaries

Dr. John Insall, an orthopedic surgeon, developed and patented knee replacement devices, which he licensed to Zimmer Biomet Holdings, Inc. In return, Zimmer agreed to pay royalties to Insall, and later to his estate after his death. When Insall’s last patent expired in 2018, Zimmer ceased royalty payments, claiming the obligation had ended. The dispute was submitted to arbitration, where the Estate prevailed. Zimmer then sought to vacate the arbitration award in district court, arguing that continuing royalty payments violated public policy. The district court confirmed the arbitration award.The United States District Court for the Northern District of Illinois reviewed the case. Zimmer argued that the arbitration award should be vacated based on public policy grounds, citing Supreme Court decisions in Brulotte v. Thys Co. and Kimble v. Marvel Entertainment, LLC, which prohibit collecting royalties on expired patents. The district court rejected Zimmer’s argument and confirmed the arbitration award, leading to Zimmer’s appeal.The United States Court of Appeals for the Seventh Circuit reviewed the case. The court emphasized the limited scope of judicial review over arbitration awards under the Federal Arbitration Act (FAA). The court found that the arbitration panel had correctly interpreted the 1998 amendments to the agreement, which untethered the royalty payments from the patents themselves, making them based on the marketing and branding of the NexGen Knee products. Consequently, the court held that the arbitration award did not violate public policy as outlined in Brulotte and Kimble. The Seventh Circuit affirmed the district court’s decision and confirmed the arbitration award in favor of Insall’s Estate. View "Zimmer Biomet Holdings, Inc. v. Insall" on Justia Law

Between November 2019 and August 2020, Core Optical Technologies, LLC filed complaints against three groups of defendants led by Nokia Corp., ADVA Optical Networking SE, and Cisco Systems, Inc. Core Optical alleged that these companies infringed on U.S. Patent No. 6,782,211, which was assigned to Core Optical by the inventor, Dr. Mark Core, in 2011. The defendants argued that the patent was actually owned by Dr. Core's former employer, TRW Inc., due to an employment-associated agreement signed by Dr. Core in 1990.The district court in the Central District of California agreed with the defendants, ruling that the 1990 agreement between Dr. Core and TRW automatically assigned the patent rights to TRW. The court found that the patent did not fall under an exception in the agreement for inventions developed entirely on the employee's own time, as Dr. Core had developed the patent while participating in a fellowship program funded by TRW.The United States Court of Appeals for the Federal Circuit vacated the district court's judgment and remanded the case for further proceedings. The appellate court found that the phrase "developed entirely on my own time" in the 1990 agreement was ambiguous and did not clearly indicate whether Dr. Core's time spent on his PhD research, which led to the invention, was considered his own time or partly TRW's time. The court concluded that further inquiry into the facts was needed to resolve this ambiguity. View "CORE OPTICAL TECHNOLOGIES, LLC v. NOKIA CORPORATION " on Justia Law

The case revolves around Intellectual Tech LLC (IT), a wholly owned subsidiary of OnAsset Intelligence, Inc. (OnAsset), and its patent dispute with Zebra Technologies Corporation (Zebra). In 2019, IT asserted U.S. Patent No. 7,233,247 against Zebra, claiming that it was the owner and assignee of the patent. However, Zebra moved to dismiss the complaint, arguing that IT lacked standing. The district court initially denied the motion, but later granted it based on its determination that IT lacked constitutional standing, leading to the dismissal of all claims without prejudice.Previously, OnAsset had granted Main Street Capital Corporation (Main Street), a lender, a security interest in its patents, including the one in question, as part of a loan agreement. When OnAsset defaulted on the loan, Main Street gained certain rights. Subsequently, OnAsset assigned the patent to IT, which also defaulted on its obligations. The district court found that Main Street's ability to license the patent upon default deprived IT of all its exclusionary rights, leading to a lack of constitutional standing.The United States Court of Appeals for the Federal Circuit disagreed with the district court's interpretation. The appellate court found that IT retained at least one exclusionary right, even considering the rights Main Street gained upon default. The court clarified that a patent owner has exclusionary rights as a baseline matter unless it has transferred all exclusionary rights away. The court concluded that IT still suffered an injury in fact from infringement even if IT and Main Street could both license the patent. Therefore, the appellate court reversed the district court's decision and remanded the case for further proceedings. View "Intellectual Tech LLC v. Zebra Technologies Corp." on Justia Law

This case revolves around an interlocutory appeal from a consolidated case between Abbott Diabetes Care, Inc., Abbott Diabetes Care Sales Corp. (collectively, “Abbott”), and DexCom, Inc. at the United States District Court for the District of Delaware. DexCom had sued Abbott for infringing its patents, leading Abbott to petition for inter partes review of the asserted patents before the Patent Trial and Appeal Board. DexCom sought a preliminary injunction to prevent Abbott from proceeding with the inter partes review proceedings based on a forum selection clause in a settlement and license agreement between the parties. DexCom appealed the district court’s denial of the preliminary injunction.The United States Court of Appeals for the Federal Circuit affirmed the district court's decision, holding that the district court did not abuse its discretion in denying the preliminary injunction. The court found that the forum selection clause in the settlement and license agreement did not preclude the filing of inter partes review petitions after the Covenant Period because it allowed them during the Covenant Period. Therefore, DexCom could not succeed on its breach-of-contract counterclaim, making it ineligible for a preliminary injunction. View "DEXCOM, INC. v. ABBOTT DIABETES CARE, INC. " on Justia Law

Uniloc brought multiple infringement suits against Google concerning patents directed to innovations in multimedia content delivery, IT security, high-resolution imaging, network connectivity, video conferencing, and image and text searching. Google alleged Uniloc lacked standing because its predecessors had granted Fortress a license and an unfettered right to sublicense to the asserted patents as part of a financing arrangement. Uniloc argued that any license had been eliminated by a Termination Agreement executed between Uniloc’s predecessors and Fortress before the suits commenced.The district court dismissed, finding that a license had been granted and survived the Termination Agreement. The Federal Circuit reversed. The district court erred in interpreting the Termination Agreement. The License Agreement granted Fortress a “non-exclusive, transferrable, sub-licensable, divisible, irrevocable, fully paid-up, royalty-free and worldwide license” to several of Uniloc’s patents, including those at issue. The Termination Agreement stated that the License Agreement “shall terminate and shall be of no further force or effect without any further documentation or action and without liability to any party hereto, and the rights of each of the applicable parties under the applicable agreement shall terminate.” By terminating the License Agreement and rights under that agreement, the Termination Agreement terminated Fortress’s license. Although the License Agreement describes the license as “irrevocable” the context clearly refers to the license’s being “irrevocable” by the licensor and does not preclude revocation by mutual agreement. View "Uniloc 2017 LLC v. Google LLC" on Justia Law

Shinyaku and Sarepta executed an Agreement concerning “a potential business relationship relating to therapies for the treatment of Duchenne Muscular Dystrophy.” During the Agreement’s term the parties would “not directly or indirectly assert or file any legal or equitable .. claim or otherwise initiate any … form of legal or administrative proceeding against the other Party . . . in any jurisdiction … concerning intellectual property in the field of Duchenne Muscular Dystrophy,” including “patent infringement litigations, declaratory judgment actions, patent validity challenges” before the U.S. Patent and Trademark Office (PTO) or Japanese Patent Office, and reexamination proceedings before the PTO. A forum selection, governing intellectual property disputes between the parties after the term’s expiration named the District of Delaware. The term ended in June 2021; the two-year forum selection clause took effect. That same day, Sarepta filed seven Patent Trial and Appeal Board petitions for inter partes review (IPR). Shinyaku filed suit in the District of Delaware asserting breach of contract (alleging that the IPR petitions violated the forum selection clause), declaratory judgment of noninfringement and invalidity concerning Sarepta’s patents, and infringement of Shinyaku’s patents.The Federal Circuit directed that the district court enter an injunction, requiring Sarepta to withdraw the petitions. The plain language of the forum selection clause resolved the dispute. View "Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics, Inc." on Justia Law

PlasmaCAM sued CNCElectronics for infringing the 441 patent, for which Plasmacam has an exclusive license. In 2019, the parties notified the district court that they had settled the case. When the parties met to draft a formal agreement, however, it became evident that they interpreted the settlement differently, and further negotiations resulted. The parties eventually advised the district court that they had reached a complete agreement. The district court granted the motion to enforce Plasmacam’s version of that agreement and ordered CNC to execute it. The Federal Circuit reversed after holding that the district court order to execute the settlement agreement constituted either an appealable injunction or a final judgment. The court concluded that CNC’s version of the agreement accurately reflects the parties’ understanding. View "PlasmaCAM, Inc. v. CNCElectronics, LLC" on Justia Law

The European Telecommunications Standards Institute (ETSI) established many global standards for 3G, 4G, and 5G cellular communications technology. ETSI members that own standard-essential patents must provide “an irrevocable undertaking in writing that [they are] prepared to grant irrevocable licenses on fair, reasonable and non-discriminatory (FRAND)” terms. Ericsson holds patents that are considered essential to the ETSI standards and agreed to grant licenses to other companies to use its standard-essential patents on FRAND terms. HTC produces mobile devices that implement those standards; to manufacture standard-compliant mobile devices, HTC has to obtain a license to use Ericsson’s patents. Ericsson and HTC have previously entered into three cross-license agreements for their respective patents. Negotiations to renew one of those agreements failed.HTC filed suit, alleging that Ericsson had breached its commitment to provide a license on FRAND terms and had failed to negotiate in good faith. The jury found in favor of the defendants. The district court entered a separate declaratory judgment that the defendants had affirmatively complied with their contractual obligations. The Fifth Circuit affirmed, rejecting challenges to the district court’s exclusion of HTC’s requested jury instructions, its declaratory judgment that Ericsson had complied with its obligation to provide HTC a license on FRAND terms, and the exclusion of certain expert testimonial evidence as hearsay. View "HTC Corp. v. Telefonaktiebolaget LM Ericsson" on Justia Law

New Vision sued SG in the federal district court in Nevada. SG then filed Patent Trial and Appeal Board petitions. The Board declined to respect the forum selection agreement in the parties’ license agreement, which referred to “exclusive” jurisdiction in the appropriate federal or state court in the state of Nevada, and proceeded to a final decision, finding the claims at issue as well as proposed substitute claims, patent-ineligible under 35 U.S.C. 101.The Federal Circuit vacated and remanded the Board’s decisions for consideration of the forum selection clause in light of its 2019 “Arthrex” decision. Because Arthrex issued after the Board’s final-written decisions and after New Vision sought Board rehearing, New Vision has not waived its Arthrex challenge by raising it for the first time in its opening brief. The Board’s rejection of the parties’ choice of forum is subject to judicial review; section 324(e) does not bar review of Board decisions “separate . . . to the in[stitu]tion decision.” View "New Vision Gaming & Development, Inc. v. SG Gaming, Inc." on Justia Law

Glaxo Group Limited and Human Genome Sciences, Inc. (collectively, “GSK”) owned patents covering Benlysta, a lupus treatment drug. GSK filed a patent application with the United States Patent and Trademark Office (“PTO”) claiming a method for treating lupus. Biogen Idec MA Inc. (“Biogen”) held an issued patent covering a similar method for treating lupus. When parties dispute who was first to discover an invention, the PTO declares an interference. Rather than suffer the delay and uncertainty of an interference proceeding, the parties agreed to settle their differences through a patent license and settlement agreement (“Agreement”). GSK ended up with its issued patent. The PTO cancelled Biogen’s patent, and Biogen received upfront and milestone payments and ongoing royalties for Benlysta sales. Under the Agreement GSK agreed to make royalty payments to Biogen until the expiration of the last “Valid Claim” of certain patents, including the lupus treatment patent. The Agreement defined a Valid Claim as an unexpired patent claim that has not, among other things, been “disclaimed” by GSK. GSK paid Biogen royalties on Benlysta sales. After Biogen assigned the Agreement to DRIT LP - an entity that purchased intellectual property royalty streams - GSK filed a statutory disclaimer that disclaimed the patent and all its claims. GSK notified DRIT that there were no longer any Valid Claims under the Agreement and stopped paying royalties on Benlysta sales. DRIT sued GSK in the Superior Court for breach of contract and breach of the implied covenant of good faith and fair dealing for failing to pay royalties under the Agreement. The court dismissed DRIT’s breach of contract claim but allowed the implied covenant claim to go to a jury trial. The jury found for DRIT, and the court awarded damages. On appeal, GSK argued the superior court should have granted it judgment as a matter of law on the implied covenant claim. On cross-appeal, DRIT claimed that, if the Court reversed the jury verdict on the implied covenant claim, it should reverse the superior court’s ruling dismissing the breach of contract claim. The Delaware Supreme Court found the superior court properly dismissed DRIT’s breach of contract claim, but should have granted GSK judgment as a matter of law on the implied covenant claim. Thus, the superior court's judgment was reversed. View "Glaxo Group Limited, et al. v. DRIT LP" on Justia Law